文献速递消化道出血消化内镜

AGA 关于非静脉曲张性上消化道出血内镜治疗的临床实践更新:专家综述

AGA Clinical Practice Update on Endoscopic Therapies for Non-Variceal Upper Gastrointestinal Bleeding: Expert Review.
PubMed 文献 · Gastroenterology · 2020-06-20

美国胃肠病学协会(AGA)研究所发布的临床实践更新,围绕10条最佳实践建议,综述非静脉曲张性上消化道出血(NVUGIB)内镜治疗的现有证据与专家经验,内容涵盖复苏与准备、常规止血技术、新型止血工具(如单极止血钳、超镜夹、止血粉)的适用场景、操作相关出血风险,以及内镜难治性出血在经导管动脉栓塞与手术间的个体化选择。

要点

  • 内镜治疗应使多数NVUGIB患者达到止血。
  • 初始处理应聚焦复苏、分诊和上消化道内镜准备,稳定后对内镜所见活动性出血或再出血高危征象进行治疗。
  • 止血粉应优先作为补救治疗而非 primary 止血,恶性出血或大量出血无法行热疗或放置止血夹时除外。

核心结论

  • 内镜治疗应使多数NVUGIB患者达到止血,内镜医师应熟悉现有止血工具与技术的适应证、疗效和局限。
  • 初始处理应聚焦复苏、分诊和内镜准备,稳定后对内镜所见活动性出血或再出血高危征象进行治疗。
  • 单极止血钳低电压凝切可作为其他机械和热治疗的替代选择,尤其适用于位置困难或基底僵硬纤维化的溃疡。
  • 止血粉应优先作为补救治疗而非 primary 止血,恶性出血或大量出血无法行热疗或放置止血夹时除外。
  • 内镜难治性NVUGIB应个体化考虑经导管动脉栓塞与手术,需综合出血病因、患者因素、再出血风险和潜在不良事件。

研究设计与样本

  • 美国胃肠病学协会(AGA)研究所临床实践更新委员会委托并批准的专家综述,经内部同行评议和《Gastroenterology》标准外部同行评议。
  • 围绕作者达成一致的10条最佳实践建议,反映该领域里程碑式和近期发表的文献以及作者经验。

主要发现

  • 内镜治疗应使多数NVUGIB患者达到止血。
  • 初始处理应聚焦复苏、分诊和内镜准备,稳定后对内镜所见活动性出血或再出血高危征象进行治疗。
  • 内镜医师应熟悉现有止血工具与技术的适应证、疗效和局限,并能熟练应用常规热疗和放置止血夹。
  • 单极止血钳低电压凝切可作为其他机械和热治疗的替代选择,尤其适用于位置困难或基底僵硬纤维化的溃疡。
  • 超镜夹止血可考虑用于常规电凝和止血夹失败或预计无效的特定NVUGIB患者。

关键数值与推荐

  • 最佳实践建议1:内镜治疗应使多数NVUGIB患者达到止血。
  • 最佳实践建议2:初始处理应聚焦复苏、分诊和内镜准备,稳定后对内镜所见活动性出血或再出血高危征象进行治疗。
  • 最佳实践建议3:内镜医师应熟悉现有止血工具与技术的适应证、疗效和局限,并能熟练应用常规热疗和放置止血夹。
  • 最佳实践建议4:单极止血钳低电压凝切可作为其他机械和热治疗的替代选择,尤其适用于位置困难或基底僵硬纤维化的溃疡。
  • 最佳实践建议5:超镜夹止血可考虑用于常规电凝和止血夹失败或预计无效的特定NVUGIB患者。

临床怎么用

  • 内镜治疗应使多数NVUGIB患者达到止血。
  • 初始处理应聚焦复苏、分诊和内镜准备,稳定后对内镜所见活动性出血或再出血高危征象进行治疗。
  • 止血粉应优先作为补救治疗而非 primary 止血,恶性出血或大量出血无法行热疗或放置止血夹时除外。
  • 内镜难治性NVUGIB应个体化考虑经导管动脉栓塞与手术,需综合出血病因、患者因素、再出血风险和潜在不良事件。
  • 不鼓励对成功内镜治疗后的高危溃疡行预防性经导管动脉栓塞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update is to review the available evidence and best practice advice statements regarding the use of endoscopic therapies in treating patients with non-variceal upper gastrointestinal bleeding. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. This review is framed around the 10 best practice advice points agreed upon by the authors, which reflect landmark and recent published articles in this field. This expert review also reflects the experiences of the authors who are gastroenterologists with extensive experience in managing and teaching others to treat patients with non-variceal upper gastrointestinal bleeding (NVUGIB). BEST PRACTICE ADVICE 1: Endoscopic therapy should achieve hemostasis in the majority of patients with NVUGIB. BEST PRACTICE ADVICE 2: Initial management of the patient with NVUGIB should focus on resuscitation, triage, and preparation for upper endoscopy. After stabilization, patients with NVUGIB should undergo endoscopy with endoscopic treatment of sites with active bleeding or high-risk stigmata for rebleeding. BEST PRACTICE ADVICE 3: Endoscopists should be familiar with the indications, efficacy, and limitations of currently available tools and techniques for endoscopic hemostasis, and be comfortable applying conventional thermal therapy and placing hemoclips. BEST PRACTICE ADVICE 4: Monopolar hemostatic forceps with low-voltage coagulation can be an effective alternative to other mechanical and thermal treatments for NVUGIB, particularly for ulcers in difficult locations or those with a rigid and fibrotic base. BEST PRACTICE ADVICE 5: Hemostasis using an over-the-scope clip should be considered in select patients with NVUGIB, in whom conventional electrosurgical coagulation and hemostatic clips are unsuccessful or predicted to be ineffective. BEST PRACTICE ADVICE 6: Hemostatic powders are a noncontact endoscopic option that may be considered in cases of massive bleeding with poor visualization, for salvage therapy, and for diffuse bleeding from malignancy. BEST PRACTICE ADVICE 7: Hemostatic powder should be preferentially used as a rescue therapy and not for primary hemostasis, except in cases of malignant bleeding or massive bleeding with inability to perform thermal therapy or hemoclip placement. BEST PRACTICE ADVICE 8: Endoscopists should understand the risk of bleeding from therapeutic endoscopic interventions (eg, endoluminal resection and endoscopic sphincterotomy) and be familiar with the endoscopic tools and techniques to treat intraprocedural bleeding and minimize the risk of delayed bleeding. BEST PRACTICE ADVICE 9: In patients with endoscopically refractory NVUGIB, the etiology of bleeding (peptic ulcer disease, unknown source, post surgical); patient factors (hemodynamic instability, coagulopathy, multi-organ failure, surgical history); risk of rebleeding; and potential adverse events should be taken into consideration when deciding on a case-by-case basis between transcatheter arterial embolization and surgery. BEST PRACTICE ADVICE 10: Prophylactic transcatheter arterial embolization of high-risk ulcers after successful endoscopic therapy is not encouraged.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Mullady DK, Wang AY, Waschke KA, et al. AGA Clinical Practice Update on Endoscopic Therapies for Non-Variceal Upper Gastrointestinal Bleeding: Expert Review. Gastroenterology. 2020. PMID: 32574620. doi:10.1053/j.gastro.2020.05.095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。